Drugs / Budesonide/Formoterol Fumarate Dihydrate
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02495168 | Jan 2017 → May 2018 | asthma | Actavis Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Budesonide/Formoterol Fumarate Dihydrate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02495168 ↗ |
| Route | Inhaled | “Oral inhalation, generic formulation of the brand-name product.” NCT02495168 ↗ |